| pubmed-article:16584285 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16584285 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:16584285 | lifeskim:mentions | umls-concept:C0008783 | lld:lifeskim |
| pubmed-article:16584285 | lifeskim:mentions | umls-concept:C0008902 | lld:lifeskim |
| pubmed-article:16584285 | lifeskim:mentions | umls-concept:C0231448 | lld:lifeskim |
| pubmed-article:16584285 | lifeskim:mentions | umls-concept:C1514468 | lld:lifeskim |
| pubmed-article:16584285 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:16584285 | lifeskim:mentions | umls-concept:C0005552 | lld:lifeskim |
| pubmed-article:16584285 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:16584285 | pubmed:dateCreated | 2006-4-4 | lld:pubmed |
| pubmed-article:16584285 | pubmed:abstractText | The extension of biowaivers (drug product approval without a pharmacokinetic bioequivalence study) to drugs belonging to Class III of the Biopharmaceutics Classification System (BCS) is currently a subject of much discussion. | lld:pubmed |
| pubmed-article:16584285 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16584285 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16584285 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16584285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16584285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16584285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16584285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16584285 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16584285 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16584285 | pubmed:issn | 0312-5963 | lld:pubmed |
| pubmed-article:16584285 | pubmed:author | pubmed-author:AmidonGordon... | lld:pubmed |
| pubmed-article:16584285 | pubmed:author | pubmed-author:DressmanJenni... | lld:pubmed |
| pubmed-article:16584285 | pubmed:author | pubmed-author:PrakongpanSom... | lld:pubmed |
| pubmed-article:16584285 | pubmed:author | pubmed-author:JantratidEkar... | lld:pubmed |
| pubmed-article:16584285 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16584285 | pubmed:volume | 45 | lld:pubmed |
| pubmed-article:16584285 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16584285 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16584285 | pubmed:pagination | 385-99 | lld:pubmed |
| pubmed-article:16584285 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:meshHeading | pubmed-meshheading:16584285... | lld:pubmed |
| pubmed-article:16584285 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16584285 | pubmed:articleTitle | Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. | lld:pubmed |
| pubmed-article:16584285 | pubmed:affiliation | Institute of Pharmaceutical Technology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany. | lld:pubmed |
| pubmed-article:16584285 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16584285 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:16584285 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:16584285 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16584285 | lld:pubmed |
